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A B S T R A C T
Introduction. A large body of literature supports the co-occurrence of depression, anxiety, and sexual dysfunction.
However, the manner in which affective symptoms map onto specific female sexual response indices is not well
understood.
Aims. The present study aimed to examine changes in depression and anxiety symptoms and their correspondence
to fluctuations in desire, subjective arousal, genital response, orgasmic function, and vaginal pain.
Methods. The study used a 2-week daily diary approach to examine same-day and temporal relations between
affective symptoms and sexual function.
Main Outcome Measures. The unique relations between shared and disorder-specific symptoms of depression and
anxiety (i.e., general distress, anhedonia, and anxious arousal) and female sexual response (i.e., desire, subjective
arousal, vaginal lubrication, orgasmic function, and sexual pain) were examined, controlling for baseline levels of
sexual distress, depression, and anxiety, as well as age effects and menstruation.
Results. Analyses revealed that changes in depression and anxiety severity corresponded to same-day variations in
sexual response. Specifically, anhedonia (depression-specific symptom) was related to poorer same-day sexual desire,
whereas greater anxious arousal (anxiety-specific symptom) was independently related to simultaneous increases in
subjective sexual arousal, vaginal lubrication, and sexual pain. Increases in general distress (i.e., shared symptoms)
were associated with greater same-day difficulties achieving orgasm. Notably, only one temporal relation was found;
it indicated that higher levels of anhedonia predicted a next-day decrease in sexual desire.
Conclusions. It is proposed that the simultaneous changes in affective symptoms and sexual function may indicate
that they are products of shared underlying mechanisms. That is, in response to stress, the processes manifesting as
feelings of weak positive affect and amotivation are the very same processes responsible for diminished capacity for
sexual desire. In contrast, the physiological hyperarousal associated with anxiety also gives rise to sexual arousal
difficulties and vaginal pain. Kalmbach DA, Kingsberg SA, and Ciesla JA. How changes in depression and
anxiety symptoms correspond to variations in female sexual response in a nonclinical sample of young
women: A daily diary study. J Sex Med 2014;11:2915–2927.
Key Words. Depression; Anxiety; Female Sexual Function; Anhedonia; Sexual Desire; Sexual Arousal; Vaginal Pain
Introduction
A large body of research has shown that womenwho suffer from depression or anxiety expe-
rience greater sexual dysfunction [1], that the
severity of these sexual difficulties corresponds to
the overall severity of the mood disorder [2], and
that depression can have a scarring effect on
female sexual functioning even after remission
of affective symptoms [3]. Some evidence also
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suggests that mood disorders constitute vulner-
abilities to sexual dysfunction and vice versa [4].
Recently, studies have demonstrated that
depression- and anxiety-specific symptoms map
onto different aspects of female sexual function
[5,6]. Prospective assessments have shown that
affective symptoms and sexual function indices
concurrently fluctuate within individuals. In other
words, irrespective of diagnostic status for a mood
disorder, when women become more depressed
(even on the more healthy end of the depression
symptom continuum), their desire decreases
simultaneously [6]. However, a number of meth-
odological limitations of past research have limited
current knowledge. Notably, much of the current
literature is based on cross-sectional data. More-
over, in the studies using repeated measures,
women reported their affective symptoms and
sexual response over the prior week or longer [6].
As evidence has supported concurrent relations,
assessment windows of a week or longer may have
failed to capture important variability in day-to-
day affective or sexual experiences, thus reducing
statistical power to detect significant relations. To
address these limitations, the current study used
ecological momentary sampling to examine daily
changes in symptoms of depression and anxiety
and corresponding variation in female sexual
function.
Sexual complaints are common in the contexts
of depression and anxiety in their many diagnostic
forms (e.g., generalized anxiety disorder, posttrau-
matic stress disorder) [1]. Importantly, these
studies suggest that diminished libido, arousal and
orgasm difficulties, and sexual pain are similarly
reported among individuals with mood and anxiety
disorders. However, given the high comorbidity
between mood and anxiety disorders, as well as
their shared features resulting in overlapping items
on measurement tools, prior research may have
been at a methodological disadvantage to detect
specificity between affective symptoms and sexual
response. Thus, it has been hypothesized that a
transdiagnostic approach (i.e., examining both
overlapping and unique dimensions of clinical
disorders) seeking to identify both shared and
disorder-specific features facilitating these rela-
tions would offer a more nuanced understanding
of the interplay between affective and sexual health
[1,5,6].
Clark and Watson’s [7] tripartite model of
anxiety and depression describes both shared and
unique features of each disorder. Specifically, the
element of general distress represents the shared
features of depression and anxiety, including fear,
sadness, low self-esteem, and feelings of being on
edge. As these features are common in both
depression and anxiety, they do not distinguish
between the two disorders. Specific to anxiety is
anxious arousal, characterized by physiological
hyperarousal symptoms, such as shaky hands,
muscle tension, and shortness of breath. Unique to
depression is anhedonia, characterized by buffered
positive affect and diminished motivation. In other
words, just as sexual function is complex and
multifactorial with several correlated yet distinct
aspects consisting of desire, subjective arousal,
physiological arousal, and orgasmic function
(among others), the structures of depression and
anxiety are intricate, with both shared and unique
components. Thus, as much of the current knowl-
edge is based on studies utilizing depression and
anxiety measures that have focused on general dis-
tress and other correlated symptoms (e.g., change
in appetite or sleep quality), disorder-specific
symptoms and their relations to these various
aspects of sexual response have been largely
overlooked.
Using the tripartite model of anxiety and
depression, two studies have taken a
transdiagnostic approach to investigate the
disorder-specific features facilitating the
co-occurrence of depression, anxiety, and sexual
dysfunction. First, Kalmbach et al. [5] used a
cross-sectional design to examine interindividual
differences in severity of anhedonia, anxious
arousal, and general distress and their relations to
female sexual response. Results indicated that
women with greater anhedonia reported lower
desire, subjective arousal, vaginal lubrication, and
orgasmic function, and greater sexual pain. In
comparison, women with greater anxious arousal
reported worse lubrication and greater pain.
General distress was not independently related to
any of these sexual function indices. These find-
ings suggested that depression-specific symptoms
(i.e., traitlike anhedonia) may constitute a vulner-
ability to a wide variety of female sexual dysfunc-
tions, whereas anxious arousal was more specific
to genital response and sexual pain. Next,
Kalmbach and colleagues [6] examined intra-
individual variations between the same con-
structs. Specifically, a sample of healthy
premenopausal women reported weekly levels of
affective symptoms and sexual function. Evidence
supported some specificity, such that when
women were more anhedonic, they experienced
poorer libido and subjective arousal during the
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same week. Additionally, when women felt more
anxiously aroused, they experienced simultaneous
changes in vaginal pain. Notably, the associations
between affective and sexual health indices were
more consistently concurrent than temporal. The
inability of a weeklong assessment window to
detect more transient fluctuations in affect and
sexual response was identified as a potential
methodological weakness. To illustrate, if Ms. A
experiences high levels of desire on Monday and
low levels of desire on Tuesday and Wednesday,
then moderate desire on Thursday and finally
high desire on Friday, Saturday, and Sunday, all
of that meaningful variation in sexual desire
cannot be captured if the daily experiences are
averaged across the week. If variations in affective
symptoms and sexual response levels are truly
concurrent, a shorter assessment window would
be necessary to detect these effects.
Aims
The present study is an extension of the prior
research on depression, anxiety, and female sexual
function using this transdiagnostic approach.
Specifically, a two-week daily ecological momen-
tary sampling approach was used to examine how
changes in depression and anxiety symptoms cor-
respond to variations in female sexual response. A
sample of young women completed daily mea-
sures of sexual response (desire, subjective
arousal, lubrication, orgasmic function, and
sexual pain), affective symptoms (general distress,
anxious arousal, and anhedonia), and daily men-
struation, as well as baseline age and higher-order
symptoms of sexual distress, depression, and
anxiety. As the women in the present sample were
relatively healthy, they were less likely to be
encumbered by confounding medical and psycho-
logical comorbidities that are more prevalent in
clinical samples. Yet, as depression and anxiety
are dimensional constructs (rather than categori-
cal), with symptom severity continuous and nor-
mally distributed in the general population [8,9],
findings were anticipated to follow a similar
pattern in unmedicated clinical populations.
Based on findings of past research on affective
symptoms and sexual response [5,6], anhedonia
was predicted to be the most consistently related
to sexual desire, as well as the most consistent
predictor of overall female sexual difficulties. In
contrast, anxious arousal was predicted to be
related to poorer lubrication and greater sexual
pain.
Methods
Participants
The participants and procedure of this study have
been described elsewhere [10]. One hundred
seventy-one women (age 20.07 ± 3.32) partici-
pated in the present study. The sample was largely
Caucasian (81.5%), with some ethnic diversity
observed (13.3% African American, 1.2% Latino
or Hispanic, 2.3% East Asian or Pacific Islander,
and 1.8% “other”). Additionally, a majority of par-
ticipants identified as mostly or completely hetero-
sexual (n = 143), whereas three participants
identified as equally sexually attracted to men and
women, and eight participants identified as mostly
or completely homosexual. Approximately 51% of
the sample reported having a significant other, and
the average length of these relationships was 20.71
months (±18.56). Fifty-sex percent of participants
(n = 96) reported having at least one current sexual
partner at baseline. Participants were recruited
from psychology courses at a Midwestern univer-
sity and received course credit for their participa-
tion. To be eligible to participate, individuals
needed to have reliable internet access at home
and to have been free of antidepressants for at least
4 weeks prior to participation. The local institu-
tional review board approved this study, and all
participants provided written informed consent.
Procedure
The study protocol involved a baseline assessment
and 14 daily assessments. At baseline, individuals
reported demographic information, sexual dis-
tress, and symptoms of depression and anxiety
over the past month. Participants then received
instructions on the daily web-delivered question-
naires, to be completed upon waking each
morning at their habitual wake time. Question-
naires assessed affective symptoms and sexual
function over the previous 24 hours.
Baseline Measures
The Center for Epidemiologic Studies Depression
Scale (CES-D) [11] is a 20-item self-report inven-
tory used to measure symptoms of depression. It
was modified to assess these symptoms over the
previous month. Scores on the CES-D range from
0 to 60. In the present sample, the CES-D
achieved high internal consistency (α = 0.90).
State-Trait Anxiety Inventory Form X—State
(STAIXS) [12] is a 20-item self-report inventory
intended to assess levels of anxiety. It was modified
to assess these symptoms over the previous month.
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Possible scores on STAIXS range from 20 to 80.
Internal consistency of STAIXS was high
(α = 0.94) in the present sample.
The Female Sexual Distress Scale—Revised
(FSDS-R) [13] is a 13-item self-report question-
naire used to assess sex-related personal distress in
women. In the present study, respondents indi-
cated the extent to which they experienced sexual
distress over the past month on a six-point Likert-
type response scale, with higher scores indicating
higher levels of sexual distress. Internal consis-
tency in the present study’s sample was good
(α = 0.74).
Main Outcome Measures
Daily Measures
TheMood andAnxiety SymptomQuestionnaire—
Short Form (MASQ) [14,15] is a 29-item self-
report measure of depression and anxiety that was
modified to ask about experiences over the past 24
hours. Three main factors assess the facets of the
tripartite model: general distress (i.e., overlapping
features of depression and anxiety; e.g., “felt tense
or high strung,” “felt depressed”), anxious arousal
(i.e., anxiety-specific symptoms; e.g., “was short of
breath,” “was trembling or shaky”), and anhedonia
(i.e., depression-specific symptoms; e.g., “felt like I
had a lot to look forward to,” “felt really happy”
[both reverse-coded]). This measure has been vali-
dated for use in students and nonclinical samples
[15] and has been shown to have good convergent
and discriminant validity [16]. See Table 1 for
descriptives.
The Profile of Female Sexual Functioning
(PFSF) [17,18] is a self-report measure of sexual
functioning that was modified for daily use in the
present study and has been validated for use in
nonclinical samples [19]. For the present study,
women reported their sexual desire, subjective
sexual arousal, and orgasmic function over the pre-
vious 24 hours. Scales consist of items on a six-
point Likert-type response scale. Each scale was
scored using raw scores, with higher scores indi-
cating better sexual function. Items specific to
sexual activity were provided with the response
choice of “no sexual activity.”1 See Table 1 for
descriptives.
The Female Sexual Function Index (FSFI) [20]
is a 19-item self-report measure of sexual function-
ing has been validated for use in normative
samples [19,21,22]. To avoid construct overlap
with the PFSF and minimize time demand of daily
assessments on participants, only the lubrication
and pain scales were administered. Both scales
were modified to measure experiences with sexual
function over the previous 24 hours and were
scored on a five-point Likert-type response scale.
In the present study, each scale was scored using
raw scores, with higher scores on the lubrication
scale indicating better sexual functioning and
higher scores on the pain scale indicating higher
levels of vaginal pain. FSFI items were presented
with a “no sexual activity” option [1]. See Table 1
for descriptives.
To assess the presence of menstruation, partici-
pants were asked each day “Have you menstruated
1These responses were treated as missing data. For indi-
viduals who had less than 25%missing data in a given scale,
proration using participants’ mean scores (within that same
scale) was used to estimate total factor scores. However,
individuals’ scale scores were treated as missing if more
than 25% of data in a factor were missing. The rationale
was that scoring a response of “no sexual activity” as 0
would artificially bias scores into indicating higher dys-
function, whereas proration allows us to estimate the total
scale score based on women’s other responses in the same
scale. However, proration was employed only when the
response rate was 75% and above so as to minimize the
impact of estimation on the data.
Table 1 Descriptive statistics and zero-order correlations between depression and anxiety scales and sexual function
indices
Factor Mean ± SD (range) α Desire Arousal Lubrication Orgasm Pain General distress Anxious arousal
Desire† 24.71 ± 10.45 (9–54) 0.94 —
Arousal† 17.19 ± 2.15 (3–18) 0.99 0.23 —
Lubrication‡ 18.57 ± 2.55 (4–20) 0.96 0.28 0.62 —
Orgasm† 20.46 ± 3.93 (4–24) 0.97 0.30 0.46 0.46 —
Pain‡ 5.21 ± 2.56 (4–20) 0.99 −0.16 −0.45 −0.32 −0.25 —
General distress§ 10.60 ± 4.23 (8–40) 0.89 −0.04 −0.24 −0.13 −0.35 0.15 —
Anxious arousal§ 11.47 ± 3.23 (10–45) 0.86 −0.02 −0.28 −0.22 −0.20 0.29 0.47 —
Anhedonia§ 22.23 ± 6.12 (8–40) 0.84 −0.28 −0.11 −0.08 −0.16 0.07 0.37 0.16
†Measured using the Profile of Female Sexual Function
‡Measured using the Female Sexual Function Index
§Measured using the Mood and Anxiety Symptom Questionnaire—Short Form
Significance values are not reported as these correlations are for descriptive purposes only
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over the past 24 hours?” and responded either
“Yes” (coded as 1) or “No” (coded as 2).
Data Analysis
To estimate time-varying outcomes, analyses were
conducted using hierarchical linear modeling
(HLM; also known as multilevel modeling). HLM
is appropriate for data that are hierarchically struc-
tured, such that level-1 variables (i.e., daily data in
the present study) are nested within level-2 units
(i.e., individual participants in the present study)
[23,24]. As such, HLM allows for the simultaneous
examination of differences between individuals
and changes within individuals. As such, this ana-
lytic approach can test the predictive qualities of
baseline reports of sexual distress, depression, and
anxiety on later sexual function; same-day associa-
tions between depression and anxiety symptoms
and female sexual response; and bidirectional tem-
poral relations between the two constructs. Impor-
tantly, HLM is robust to missing data, which are
common in repeated-measures studies [24].
Preliminary Analyses
To investigate the influence of baseline character-
istics on female sexual function (for individual i at
time t), it was tested whether index of sexual
response was predicted by age (for individual i) and
baseline sexual distress, depression, and anxiety
(for individual i), controlling for presence of men-
struation (for individual i at time t). These analyses
were conducted to determine relevant covariates
for the models testing study hypotheses. An
example model (Example 1) follows.
Desire Depression Anxiety
Sexual Distress
it i i i
i
= + +
+ +
β β β
β β
0 1 2
3 4Age
Menstruation
i
it i it+ + +β ζ ε5 0
Example 1 revealed differences in sexual response
outcomes for women with varying levels of base-
line depression, anxiety, and sexual distress. Addi-
tionally, this model revealed any influence of age
effects and menstruation. Subsequent analyses
included significant predictors as covariates to
allow for the testing of relations between daily
affect and sexual function independent of
higher-order symptoms of anxiety and depression,
sexual distress, age effects, and impact of daily
menstruation.
Substantive Hypotheses
To examine day-to-day covariation between symp-
toms of anxiety or depression and female sexual
function, sexual function was first regressed onto
the same day’s anhedonia, anxious arousal, and
general distress while controlling for relevant
covariates, as in Example 2 below.
Desire General Distress
Anxious Arousal Anhe
it i it
it
= +
+ +
β β
β β
0 1
2 3 donia
Covariates
it
i t i it+ … + +( )β ζ ε4 0
To examine temporal relations, sexual function was
regressed on the previous day’s depression and
anxiety symptoms while controlling for relevant
covariates and the lagged value of the outcome
variable. When the previous day’s outcome vari-
able is controlled for (i.e., at time t − 1), any sig-
nificant relations between affect at time t − 1 and
sexual function at time t are independent of the
impact of the previous day’s sexual functioning and
represent a change from the previous day’s sexual
function. In examining sexual function’s impact on
the following day’s affective experience, analyses
were run in the same manner in which the lagged
relations in the opposite direction were conducted.
Results
Preliminary Analyses
Based on scores on the FSDS-R,2 19.30% of
women in the present study reported clinically rel-
evant sexual distress (mean score 19.81 ± 11.24).
Regarding affective symptoms, 3% of participants
reported clinical levels of baseline depression
(mean CES-D score 13.37 ± 9.78) [25], whereas
9% reported clinical anxiety (mean STAIXS
score 41.92 ± 10.98) [26]. See Table 1 for bivariate
correlations between daily affective symptoms
and sexual function indices, which are presented
for descriptive purposes to orient the reader
to the data. Finally, participants were highly com-
pliant, as evidenced by the average number of
daily assessments completed being 13 (SD ± 1.79;
out of a possible total of 15 [baseline + 14 daily
assessments]).
Concurrent Models
Desire
First, an unconditional-means (i.e., null) model
was run with sexual desire regressed on an inter-
cept, a level-1 (within-person) residual, and a
2Rather than the original 0–4 scale, the present study
administered the FSDS-R using a 1–6 scale. As such, a
clinical cutoff of 27, rather than 11, was used to adjust for
the scaling difference.
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level-2 (between-person) residual. Results showed
that approximately 54% of the total variance in
sexual desire was due to day-to-day fluctuations,
thus supporting the examination of time-varying
outcomes. Next, a multilevel model regressing
sexual desire on menstruation, age, and baseline
anxiety, depression, and sexual distress was run (see
Table 2).3 Analyses showed that women reported
greater sexual desire when they were not menstru-
ating (P < 0.01). As such, menstruation was
included as a covariate in all subsequent models in
which sexual desire was the outcome variable. No
other predictors were significant.
Next, a HLM model examining the concurrent
relations between desire and anhedonia, anxious
arousal, and general distress, controlling for men-
struation, was run (see Table 2). Analyses revealed
that women experienced poorer sexual desire
when they were more anhedonic (P < 0.001).
Neither anxious arousal nor general distress was
independently related to same-day sexual desire.
Menstruation remained a significant predictor,
such that women reported greater desire for sex
when they were not menstruating (P < 0.01).
Subjective Arousal
The null model estimated that approximately 44%
of the total variance in subjective arousal was due
to daily fluctuations. Next, analyses revealed that
greater age (P = 0.02) and sexual distress (P < 0.01)
predicted lower levels of arousal (see Table 3).
Then, a HLM model testing covariation between
affective symptoms and sexual response indices,
controlling for age and sexual distress, was run.
Results revealed that women reported poorer sub-
jective arousal when they experienced greater
anxious arousal (P = 0.03). Further, the relation
between general distress and arousal approached
significance (P = 0.06), suggesting that women
3In multilevel modeling, the χ2 statistic reflects the differ-
ence between the tested model and a null model with no
predictors. Thus, a significant χ2 is desirable, as it is indica-
tive of a model that accounts for significant variance in the
outcome. This is in contrast to the use of χ2 in structural
equation modeling, in which significant χ2 statistics are
undesirable and reflect a lack of model fit.
Table 2 Regression of desire (Desireit) on depression and anxiety symptoms
Outcome Predictor Β† z‡ P value§ χ2 (P value)
Determination of covariates
(N = 171, Obs = 2,186)
Level 1 14.31 (0.01)
Intercept 28.07 6.65 <0.001
Menstruationit 1.64 3.03 <0.01
Level 2
Anxietyi −0.05 −0.56 0.58
Depressioni −0.06 −0.70 0.49
Sexual Distressi 0.10 1.84 0.07
Age −0.22 1.36 0.18
Concurrent model (N = 171,
Obs = 2,182)
Level 1 188.45 (<0.001)
Intercept 33.66 21.53 <0.001
General Distressit −0.10 −1.45 0.15
Anxious Arousalit 0.01 0.09 0.93
Anhedoniait −0.50 −11.40 <0.001
Menstruationit 1.66 3.20 <0.01
Temporal model (N = 171,
Obs = 1,906)
Level 1 65.89 (<0.001)
Intercept 20.77 11.20 <0.001
General Distressit−1 0.07 0.95 0.34
Anxious Arousalit−1 0.04 0.50 0.62
Anhedoniait−1 −0.17 −3.51 <0.001
Menstruationit 1.81 3.08 <0.01
Desireit−1 0.12 5.24 <0.001
†Unstandardized beta coefficient
‡Test of statistical significance for individual predictors
§Significance value
Desire measured using the Profile of Female Sexual Function
General distress, anxious arousal, and anhedonia measured using the Mood and Anxiety Symptom Questionnaire—Short Form
Depression measured using the Center for Epidemiologic Studies Depression Scale
Anxiety assessed using State-Trait Anxiety Inventory Form X—State
Obs = number of observations
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may experience diminished subjective arousal
when feeling distressed. Notably, age (P < 0.01)
and sexual distress (P < 0.01) remained significant
predictors, whereas anhedonia was nonsignificant.
Vaginal Lubrication
The null model indicated daily fluctuations
accounted for 48% of the total variance in vaginal
lubrication. Next, analyses revealed that increased
age predicted poorer lubrication (P < 0.01; see
Table 4). Then, a HLM model examining how
affective symptoms predicted daily sexual
response, controlling for age, was run. Estimation
suggested that women reported more difficulty
producing and maintaining vaginal lubrication
when they experienced greater anxious arousal
(P < 0.01). Neither anhedonia nor general distress
was significant. Age remained a significant predic-
tor (P < 0.01).
Orgasmic Function
The null model estimated that day-to-day changes
accounted for approximately 43% of the variance
in orgasmic function. Next, results revealed that
older women (P = 0.02) and women with greater
sexual distress (P < 0.05) reported poorer orgasmic
function later on (see Table 5). Next, orgasmic
function was predicted by affective symptoms,
controlling for age and sexual distress. Results of
the HLM model showed that women reported
poorer orgasmic function when they were more
distressed (P = 0.02). Neither anehdonia nor
anxious arousal was significant, whereas age
(P = 0.02) and sexual distress (P = 0.01) remained
significant.
Vaginal Pain
The null model indicated that approximately 46%
of the total variance in vaginal pain was due to
daily fluctuations. Next, analyses revealed that
women with greater baseline sexual distress
reported greater vaginal pain (P = 0.05; see
Table 6). Then, covariation between affective
symptoms and vaginal pain was tested, controlling
for sexual distress. Analyses estimated that women
reported greater vaginal pain when they were
more anxiously aroused (P = 0.01). Neither
general distress nor anhedonia was significant,
whereas sexual distress remained a significant pre-
dictor of vaginal pain (P = 0.01).
Temporal Relations
Temporal relations between symptoms of depres-
sion and anxiety and female sexual response
were next examined. First, sexual response was
regressed on the previous day’s affective symptoms
Table 3 Regression of subjective arousal (Arousalit) on depression and anxiety symptoms
Outcome Predictor Β† z‡ P value§ χ2 (P value)
Determination of covariates
(N = 144, Obs = 584)
Level 1 19.53 (<0.01)
Intercept 20.81 16.27 <0.001
Menstruationit −0.27 −1.21 0.23
Level 2
Anxietyi −0.01 0.30 0.76
Depressioni 0.01 0.34 0.73
Sexual Distressi −0.06 −2.79 <0.01
Agei −0.12 −2.33 0.02
Concurrent model (N = 144,
Obs = 583)
Level 1 34.93 (<0.001)
Intercept 21.43 21.41 <0.001
General Distressit −0.04 −1.89 0.06
Anxious Arousalit −0.05 −2.22 0.03
Anhedoniait −0.01 −0.42 0.68
Level 2
Sexual Distressi −0.04 −2.74 <0.01
Agei −0.12 −2.67 <0.01
†Unstandardized beta coefficient
‡Test of statistical significance for individual predictors
§Significance value
Arousal measured using the Profile of Female Sexual Function
General distress, anxious arousal, and anhedonia measured using the Mood and Anxiety Symptom Questionnaire—Short Form
Depression measured using the Center for Epidemiologic Studies Depression Scale
Anxiety assessed using State-Trait Anxiety Inventory Form X—State
Obs = number of observations
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while controlling for the previously identified
covariates and the outcome variable’s lagged value.
However, given the large number of correlated
predictors (particularly the lagged outcome value’s
addition), overdetermination of the model was a
concern. Thus, to rule out spurious findings, any
models with significant predictors were rerun
without covariates, as replication would suggest
Table 4 Regression of vaginal lubrication (Lubricationit) on depression and anxiety symptoms
Outcome Predictor Β† z‡ P value§ χ2 (P value)
Determination of covariates
(N = 137, Obs = 483)
Level 1 15.09 (0.01)
Intercept 23.20 15.13 <0.001
Menstruationit −0.32 −0.89 0.37
Level 2
Anxietyi −0.01 −0.46 0.65
Depressioni 0.01 0.34 0.73
Sexual Distressi −0.03 −1.64 0.10
Agei −0.16 −2.96 <0.01
Concurrent model (N = 137,
Obs = 484)
Level 1 26.67 (<0.001)
Intercept 23.94 19.96 <0.001
General Distressit −0.04 −1.33 0.18
Anxious Arousalit −0.09 −2.72 <0.01
Anhedoniait −0.02 −0.82 0.41
Level 2
Agei −0.18 −3.43 <0.01
†Unstandardized beta coefficient
‡Test of statistical significance for individual predictors
§Significance value
Lubrication measured using the Female Sexual Function Index
General distress, anxious arousal, and anhedonia measured using the Mood and Anxiety Symptom Questionnaire—Short Form
Depression measured using the Center for Epidemiologic Studies Depression Scale
Anxiety assessed using State-Trait Anxiety Inventory Form X—State
Obs = number of observations
Table 5 Regression of orgasmic function (Orgasmit) on depression and anxiety symptoms
Outcome Predictor Β† z‡ P value§ χ2 (P value)
Determination of covariates
(N = 136, Obs = 533)
Level 1 17.16 (<0.01)
Intercept 26.57 11.41 <0.001
Menstruationit −0.06 −0.14 0.89
Level 2
Anxietyi 0.02 0.36 0.72
Depressioni −0.06 −1.12 0.26
Sexual Distressi −0.07 −1.99 <0.05
Agei −0.20 −2.36 0.02
Concurrent model (N = 136,
Obs = 533)
Level 1 27.51 (<0.001)
Intercept 26.59 14.54 <0.001
General Distressit −0.11 −2.36 0.02
Anxious Arousalit −0.03 −68 0.50
Anhedoniait −0.01 −0.45 0.66
Level 2
Sexual Distressi −0.07 −2.51 0.01
Agei −0.18 −2.28 0.02
†Unstandardized beta coefficient
‡Test of statistical significance for individual predictors
§Significance value
Orgasmic function measured using the Profile of Female Sexual Function
General distress, anxious arousal, and anhedonia measured using the Mood and Anxiety Symptom Questionnaire—Short Form
Depression measured using the Center for Epidemiologic Studies Depression Scale
Anxiety assessed using State-Trait Anxiety Inventory Form X—State
Obs = number of observations
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findings were not due to multicollinearity artifacts
(i.e., “bouncing betas”).
As anticipated, fewer temporal effects were
found. Specifically, results indicated that anhedo-
nia predicted a next-day decrease in sexual desire,
but did not predict any other sexual function
outcome (P < 0.001; see Table 2). The follow-up
model without the menstruation covariate or pre-
vious day’s lagged outcome variable (i.e., regress-
ing desire only on previous-day anhedonia,
general distress, and anxious arousal) replicated
this finding (β = −0.22, z = −4.59, P < 0.001). The
only other significant temporal finding was that
anxious arousal predicted poorer orgasmic func-
tion the following day (β = −0.12, z = −1.97,
P < 0.05). To rule out poor beta estimation, a
HLM model was run regressing orgasmic function
only on previous-day general distress, anxious
arousal, and anhedonia. Analyses revealed that
anxious arousal was no longer a significant predic-
tor of next-day orgasmic function (β = −0.08,
z = −1.59, P = 0.11). Thus, the finding was inter-
preted as a Type I error.
Models regressing affective symptoms on
previous-day sexual functioning were conducted in
the same manner as the previously described
models. Null models revealed large day-to-day
variation in affective symptoms (47–52%).
However, when regressing general distress,
anxious arousal, and anhedonia on previous-day
female sexual function indices, no significant tem-
poral relations were found.
Discussion
Using a 2-week repeated-measures design, the
present study sought to describe changes in
depression and anxiety symptoms and their corre-
spondence to day-to-day variations in female
sexual response. Evidence supported specificity
between depression and anxiety, as disorder-
specific symptoms fluctuated with indices of sexual
desire, arousal, vaginal lubrication, orgasmic func-
tion, and sexual pain. Notably, these relations were
more concurrent than temporal.
As clinically significant depression and anxiety
involve chronically severe levels of anhedonia
(depression-specific), anxious arousal (anxiety-
specific), and general distress (both depression and
anxiety), these findings offer insight into the evo-
lution of comorbid depression, anxiety, and sexual
dysfunction. Notably, depression-specific anhedo-
nia and sexual desire were found to be closely
related, both concurrently and temporally. Specifi-
cally, when women were less motivated and less
happy, they desired less sexual activity. Further,
these feelings of anhedonia corresponded to
decreases in desire the following day, though the
Table 6 Regression of vaginal pain (Painit) on depression and anxiety symptoms
Outcome Predictor Β† z‡ P value§ χ2 (P value)
Determination of covariates
(N = 130, Obs = 447)
Level 1 12.53 (<0.001)
Intercept 2.30 1.46 0.15
Menstruationit 0.42 1.16 0.25
Level 2
Anxietyi 0.05 1.72 0.09
Depressioni −0.04 −1.12 0.26
Sexual Distressi 0.04 1.94 0.05
Agei 0.02 0.42 0.67
Concurrent model (N = 130,
Obs = 448)
Level 1 15.10 (<0.01)
Intercept 3.54 5.59 <0.001
General Distressit−1 −0.02 −0.76 0.45
Anxious Arousalit 0.09 2.55 0.01
Anhedoniait −0.00 −0.08 0.93
Level 2
Sexual Distressi 0.05 2.67 0.01
†Unstandardized beta coefficient
‡Test of statistical significance for individual predictors
§Significance value
Pain measured using the Female Sexual Function Index
General distress, anxious arousal, and anhedonia measured using the Mood and Anxiety Symptom Questionnaire—Short Form
Depression measured using the Center for Epidemiologic Studies Depression Scale
Anxiety assessed using State-Trait Anxiety Inventory Form X—State
Obs = number of observations
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effect size was smaller in the temporal relation (see
Table 2). This result is consistent with the finding
that greater feelings of happiness and enthusiasm
co-occur with higher levels of desire as well as
increased desire the following day in this sample
[27]. The simultaneous changes in anhedonia and
desire suggest a shared pathophysiology. Dopa-
minergic activity is related to a lack of pleasure and
depression (see Treadway and Zald [28] for review)
and to the neurobiology of sexual desire [29],
which may represent a direct link between desire
and anhedonia. Alternatively, these covariations
may be the product of hormonal changes related
to the hypothalamic–pituitary–adrenal and
hypothalamic–pituitary–gonadal axes (see [30] for
review on the neuroendocrinology of anhedonia).
These hypotheses are for potential future study.
Regarding directionality, the temporal relation
found in this study is consistent with depression-
specific symptoms conferring a unique affective
vulnerability to hypoactive sexual desire. That is,
experiences of anhedonia have a lingering impact
on later desire levels in women.
In comparison, the physiological hyperarousal
component of anxiety was related to subjective and
physiological arousal and vaginal pain. That is,
when women experienced more somatic tension,
shortness of breath, and other anxious arousal
symptoms, they experienced poorer subjective
arousal and vaginal lubrication, as well as greater
sexual pain. Importantly, these relations were
strictly concurrent. Unlike the relation between
anhedonia and desire, today’s physiological
hyperarousal has no independent impact on tomor-
row’s sexual response. However, these associations
are consistent with autonomic dysregulation as a
shared risk factor for comorbid anxiety and dys-
functional female sexual arousal and vaginal pain.
That is, physiological hyperarousal symptoms in
response to stress may manifest as both anxiety and
sexual difficulties.
Finally, general distress was related to same-day
orgasmic function. When women were more
fearful, more discouraged, and experiencing
poorer self-worth, they had greater difficulty
achieving orgasm. This suggests that symptoms
common to both depression and anxiety interfere
with the ability to achieve orgasm. Past research
has shown that cognitive distraction from erotic
stimuli is related to orgasmic dysfunction [31].
Given that intrusive and perseverative thoughts in
the forms of worry and rumination are common to
both depression and anxiety disorders [32,33], it is
possible that these cognitive processes drive the
relation between general distress and orgasmic
function.
To sum, the relations between affective and
sexual health have been traditionally viewed as
bidirectional, such that depression and anxiety can
lead to sexual dysfunction and vice versa. However,
given that relations were largely concurrent, an
alternative (though not mutually exclusive) expla-
nation may be that affective and sexual dysfunction
symptoms may be manifestations of the same
underlying processes. That is, in the face of a
stressor, a woman is likely to experience some
degree of change in depression and/or anxiety
symptoms (irrespective of higher-order or baseline
symptoms, as demonstrated in this study) and that
the same neurobiological, physiological, and cog-
nitive processes effecting change in affective pre-
sentation produce corresponding changes in one’s
capacity for sexual response. For instance, Ms. X is
exposed to a stressor, which results in reduced hap-
piness, low motivation, and less capacity for men-
tally connecting with sexual interests or fantasies.
In contrast, Ms. Y faces a stressor and develops
co-occurring anxious hyperarousal and sexual
arousal difficulties, whereas Ms. Z perseverates on
a stressor, which increases feelings of both fear and
discouragement and interferes with her ability to
achieve orgasm. In other words, the mechanisms
facilitating these relations are the same within
individuals. However, not all individuals who
experience greater anhedonia or anxious arousal
will also experience significantly diminished desire
or sexual arousal, or vice versa. Thus, premorbid
vulnerabilities and protective factors for depres-
sion, anxiety, and sexual dysfunction would
differentiate between individuals who develop
symptoms following stressors and those who are
more resistant. That affective symptoms and
capacity for female sexual response may be mani-
festations of the same cognitive, neurobiological,
and autonomic processes is consistent with these
findings, but it is a hypothesis to be more fully
explored in future study.
Additionally, these findings have implications
for the replacement of the DSM-IV-TR’s [34]
hypoactive sexual desire disorder (HSDD) and
female sexual arousal disorder (FSAD) with female
sexual interest/arousal disorder in the DSM-5
[35]. Past research has offered conflicting evidence
regarding whether or not HSDD and FSAD
capture distinct disorders [36–39] or are better
described by one overarching disorder [40–43]. As,
in our study, desire was uniquely related to blunted
positive affect and amotivation, whereas both
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arousal indices (subjective and genital response)
were uniquely related to physiological
hyperarousal, it appears that the affective symp-
toms complicit in desire and arousal difficulties
differ. Merging desire and arousal disorders into a
single disorder suggests, though perhaps not
intentionally, that desire and arousal comprise a
unitary construct. This conceptualization is not
consistent with their relations with different psy-
chological factors, as evidenced in this study as
well as in an investigation of daily normative affect
and female sexual response [27]. If desire and
arousal do not comprise a singular construct, the
appropriateness of merging dysfunctional sexual
desire and arousal into a single disorder must be
called into question.
The results of this study should be interpreted in
the context of certain limitations. Notably, the
sample consisted of young women, who are less
likely to present with severemedical or psychologi-
cal health issues as compared with older or clinical
samples. This study benefited from a relatively
healthy sample, which allowed the study of affective
symptoms and sexual response in women who were
less likely to be encumbered by other potentially
confounding medical or psychological comorbi-
dities as compared with a clinical sample. However,
it is important to test these relations in less psycho-
logically or sexually healthy populations to identify
potential characteristics that may impact or mod-
erate these relations, such as cardiovascular disease
and various health behaviors. Future studies are
also necessary to determine whether these results
generalize to older women and men. An additional
potential limitation regards range restriction and
statistical power. A number of affective symptoms
(i.e., general distress and anxious arousal) and
sexual response indices (i.e., subjective arousal,
lubrication, orgasmic function, and sexual pain)
were marked by range restriction. Specifically, the
mean values of these indices were within a single
standard deviation of the “healthy” end of the scale.
As such, it is possible that this restriction reduced
statistical power to detect some effects. Also, the
present study consisted of 14 daily assessments.
Given the relation between phases of themenstrual
cycle and female sexual response [29,44], future
endeavors may consider examining how hormonal
changes may influence daily affect and sexual
response, or even moderate this relation.
Conclusions
The findings of the present study indicated that
changes in affective symptoms and sexual response
occur simultaneously. Notably, sexual problems
did not appear to be symptoms of depression
or anxiety, nor did depression or anxiety appear to
be symptoms of sexual dysfunction. As such, it is
proposed that symptoms of depression, anxiety,
and psychogenic sexual dysfunction may represent
manifestations of the same underlying processes.
This conceptualization is a shift from other
theories proposing that depression and anxiety
cause sexual dysfunction, or vice versa; however, it
is not mutually exclusive with these aforesaid
theories regarding causation. That is, it is
possible that anhedonic depression may lead to
clinically hypoactive desire (which is consistent
with the finding of a temporal association for
anhedonia, which predicted next-day desire) and
simultaneously be a product of the same neurobio-
logical, physiological, or cognitive processes (con-
sistent with the many findings of concurrent
associations).
The results of the present study may inform
clinical decisions in tailoring intervention based on
the presenting affective and sexual complaints.
Mindfulness therapy has been gaining support as a
viable treatment option for women presenting
with a wide variety of sexual dysfunction presen-
tations, including desire, arousal, and pain com-
plaints [45–48]. Notably, increased mindfulness
has been shown to reduce perseverative thoughts
[49–51] and physiological arousal [51], and these
may constitute some of the key ingredients of
mindfulness therapy for sexual dysfunction, par-
ticularly arousal, orgasm, and pain difficulties.
Additionally, owing to the evidence showing a
close relation between physiological hyperarousal
and sexual arousal and pain, increased emphasis on
adjunctive relaxation training is recommended for
women presenting with these sexual difficulties.
On the other hand, emphasizing techniques aimed
at targeting the wandering mind (e.g., “turning the
mind”) and emotion regulation for individuals
who present with otherwise treatment-refractory
orgasmic dysfunction may enhance treatment out-
comes. Importantly, adding a behavioral activation
component to increase overall positive affect and
reinforce engagement in pleasurable and mastery
activities (thus improving global motivation)
may increase capacity for sexual desire, thus
increasing the effectiveness of other current prac-
tices targeting diminished libido. Of course, as the
many aspects of sexual response are interrelated,
symptom relief in one area is likely to correspond
to improvements in other areas of functioning.
Overall, the evidence provided in this study has
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important implications for the nosology of depres-
sion, anxiety, and sexual function disorders and
their treatment.
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